Your Opioid Response Is Genetic. Here's Why Dosing Doesn't Work One-Size-Fits-All.

Your mu-opioid receptors are the locks on your pain-signaling neurons. When an opioid molecule binds to one of these receptors, it triggers pain relief. OPRM1 encodes the structure of that receptor. A normally functioning receptor responds to opioids at standard doses. But a single genetic variant can change the shape of that receptor just enough to reduce its sensitivity to opioid binding.

The A118G variant, carried by roughly 10-15% of people with European ancestry (and up to 40% in East Asian ancestry), creates a receptor that binds opioids less efficiently. People with the G allele may require significantly higher doses of opioids to achieve the same pain relief as those without the variant. This isn’t tolerance from repeated use. This is your baseline receptor sensitivity, set before you ever take a single dose.

You notice this most acutely when you’re prescribed a standard opioid dose and it barely touches your pain, or when friends and family members get relief from doses that do nothing for you. You’re not being difficult or exaggerating your pain. Your receptors are literally less responsive to the medication. The solution isn’t more opioids in a trial-and-error fashion; it’s understanding your variant status so your doctor can prescribe with that knowledge built in.

COMT is the enzyme that breaks down dopamine and norepinephrine in your prefrontal cortex and pain-processing regions. These catecholamines are central to pain modulation. When COMT is working at normal speed, it clears these neurotransmitters at the right pace, and your pain circuits stay balanced. When COMT is slow, catecholamines accumulate, and your brain becomes hypersensitive to pain signals. This is why slow COMT is associated with lower pain thresholds and central sensitization.

The Val158Met variant determines COMT activity. Roughly 25% of people with European ancestry are homozygous for the slow variant (Met/Met). Slow COMT carriers experience amplified pain signaling because their brain can’t clear pain-modulating neurotransmitters efficiently, leaving pain signals in a heightened state. This is particularly relevant for opioid sensitivity: if your baseline pain perception is already elevated due to slow COMT, you may genuinely need higher opioid doses, not because your opioid receptors are insensitive, but because your pain signal is inherently louder.

You’ll recognize this if you’ve always been sensitive to pain, if stress makes your pain dramatically worse, or if you notice that caffeine (which increases catecholamine levels) significantly worsens your discomfort. Your pain circuits are hypersensitive by default. Standard pain dosing doesn’t account for this. Genetic testing does.

BDNF (brain-derived neurotrophic factor) is a protein that shapes how your nervous system learns. It’s crucial for memory formation, learning, and neuroplasticity. In the context of pain, BDNF drives central sensitization, a process where your spinal cord and brain amplify pain signals over time, making you more sensitive to the same stimulus. Chronic pain often involves escalating central sensitization, and BDNF is one of the main drivers.

The Val66Met variant affects BDNF’s activity and release. Roughly 30% of people carry the Met allele, which is associated with altered pain sensitivity and increased central sensitization. People with the Met allele may experience more rapid escalation of pain sensitivity and stronger learning of pain patterns, meaning chronic pain can worsen more quickly and become harder to reverse. This is critical for opioid management because central sensitization is one of the mechanisms that drives opioid tolerance: as your nervous system amplifies pain signals, you need higher doses to achieve the same effect.

You notice this as pain that seems to get worse over time even without new injury, pain that spreads to other parts of your body, or pain that becomes chronic after an acute injury that should have healed. Your BDNF variant means your nervous system is learning pain patterns more aggressively. Opioids alone won’t solve this; your strategy needs to include interventions that reverse central sensitization, such as specific exercise, neuromodulation, or neuropathic pain medications.

GCH1 encodes GTP cyclohydrolase 1, an enzyme that synthesizes tetrahydrobiopterin (BH4), a critical cofactor for producing dopamine, serotonin, and nitric oxide. These are all pain-modulating neurotransmitters. In your pain-processing regions, BH4 is essential for your brain to manufacture its own natural pain relief. When GCH1 function is reduced by genetic variants, your capacity to produce BH4 declines, and your endogenous pain-relief capacity shrinks.

GCH1 variants are carried by roughly 15-20% of the population and are associated with reduced pain tolerance and heightened pain sensitivity. People with GCH1 variants that reduce enzyme activity have lower natural pain-buffering capacity, meaning their pain sensitivity is higher at baseline and their ability to self-soothe pain is diminished. This is why some people have always been more pain-sensitive than others, even before injury or illness.

You notice this as someone who’s been pain-sensitive your entire life, even as a child. Minor injuries hurt more than they seem to for others. You may also notice that standard pain-relief interventions (rest, ice, heat) don’t help as much as they should. Your nervous system simply doesn’t produce as much natural pain relief. This is foundational information for opioid dosing: your baseline pain sensitivity is legitimately higher, and standard dosing algorithms don’t account for this genetic reality.

FAAH is the enzyme that breaks down anandamide, your body’s endogenous cannabinoid. Anandamide is a naturally produced pain-relief molecule. When FAAH is working at normal speed, anandamide is rapidly degraded, limiting its painkilling effect. When FAAH is less active due to genetic variants, anandamide accumulates to higher levels, and pain relief is amplified. This is why FAAH variants are protective against pain sensitivity.

The C385A variant (A allele) reduces FAAH activity. Roughly 20-30% of people carry the A allele, and carriers have higher resting anandamide levels and lower baseline pain sensitivity. People with the A allele experience naturally higher endocannabinoid tone, meaning their body produces more pain relief from its own internal cannabinoid system. This is one of the reasons some people are naturally pain-resilient: they’re bathing their pain circuits in endogenous pain relief.

You recognize this as someone who’s always been less pain-sensitive than peers, even when injured. You recover quickly from pain. If this is you, it affects your opioid needs: you may require lower doses or less frequent dosing than clinical guidelines suggest. Conversely, if you don’t carry the A allele, your endocannabinoid system is less robust, and you might benefit from strategies that enhance it (like specific cannabinoid-based medicines, where legal and appropriate, or exercises that boost endogenous anandamide production).

MTHFR encodes methylenetetrahydrofolate reductase, the enzyme that converts folate into its active form for methylation reactions throughout your body. Methylation is how your cells regulate gene expression, produce neurotransmitters, and manage inflammation. In pain processing, methylation supports the production and modulation of serotonin, dopamine, and other pain-relieving neurochemicals. When MTHFR is less efficient due to genetic variants, your methylation capacity declines, and your ability to support pain-modulating neurotransmitter production suffers.

The C677T variant, carried by roughly 40% of people with European ancestry, reduces MTHFR enzyme activity by 35-70%. People with one or two copies of the T allele have impaired methylation capacity, meaning their cells can’t efficiently convert dietary folate into the active forms needed to support pain-relieving neurotransmitter production and regulate inflammation. This compounds pain sensitivity: you’re not producing enough serotonin or dopamine because the methylation machinery that makes these neurotransmitters is running at reduced capacity.

You notice this as chronic pain paired with low mood, fatigue, or inflammation that doesn’t respond well to standard supplements. Your standard multivitamin contains folic acid, which your impaired MTHFR can’t convert efficiently. You’re getting very little benefit from routine B-vitamin supplementation. When opioids are part of your pain management strategy, MTHFR variants matter because your pain-modulating neurotransmitter system is already compromised by poor methylation support. Standard opioid dosing doesn’t account for this underlying metabolic deficit.